Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 5/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 2/20 | 0.42 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28169774 | 0.85 | CXCR4 (0.64) | CXCR4ACHEBACE1CCR3 | |
| SCHEMBL803087 | 0.82 | ACHE (0.49) | ACHESIGMAR1HIF1AEPAS1CCR3 | |
| SCHEMBL21101233 | 0.79 | SIGMAR1 (0.50) | CXCR4ACHESIGMAR1HIF1AEPAS1 | |
| SCHEMBL19160313 | 0.79 | KDM4E (0.49) | ACHESIGMAR1CCR3 | |
| SCHEMBL14019295 | 0.77 | DRD2 (0.51) | ACHESIGMAR1HIF1AEPAS1 | |
| SCHEMBL803095 | 0.77 | HSD11B1 (0.47) | ACHESIGMAR1HIF1AEPAS1CCR3 | |
| SCHEMBL23012935 | 0.76 | SIGMAR1 (0.56) | CXCR4ACHESIGMAR1 | |
| SCHEMBL17030671 | 0.76 | MEN1 (0.56) | ACHESIGMAR1HIF1AEPAS1 | |
| SCHEMBL4700463 | 0.76 | ACHE (0.49) | ACHESIGMAR1HIF1AEPAS1CCR3 | |
| SCHEMBL4700460 | 0.76 | ACHE (0.49) | ACHESIGMAR1HIF1AEPAS1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065883-A1 | Triazolo [4, 5- B] Pyridin Derivatives | Centro Nacional de Investigaceiones Oncologicas (CNIO) (ES) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065883-A1 | Triazolo [4, 5- B] Pyridin Derivatives | PIM1, PIM3, PIM2 | CXCR4 1626/4885ACHE 4403/4885SIGMAR1 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.